Epiduo® (Adapalene and Benzoyl Peroxide) Gel 0.1%/2.5% Pump, Cetaphil® DermaControl™ Moisturizer SPF 30, and Cetaphil® DermaControl™ Foam Wash Regimen in Student Athletes With Mild to Moderate Acne Vulgaris

Inclusion Criteria:

1. Male and females aged 12 years and older who are actively participating in one of 14
Texas University Interscholastic League (UIL) sanctioned athletic activities at the
baseline visit (Baseball; Basketball; Cross Country; Football; Golf; Soccer;
Softball; Swimming and Diving; Team Tennis; Tennis; Track and Field; Volleyball; and
Wrestling).

2. Subjects who agree to be photographed at each visit.

3. Diagnosed with acne vulgaris by a BCD and eligible for treatment with Epiduo®
(adapalene and benzoyl peroxide) Gel 0.1%/2.5% per PI.

4. Female subjects must have a negative urine pregnancy test (UPT) at Baseline/Visit 1,
must be willing to have this test performed at the clinic, and must agree to practice
one form of effective methods of non-hormonal contraception for the duration of the
study which include: abstinence, IUD (inserted 30 days prior to baseline),
double-barrier method, bilateral tubal ligation, or vasectomized partner (at least 90
days prior to baseline).

5. A minimum of 20 but not more than 50 inflammatory (papules and pustules) lesions on
the face (excluding the nose) and a minimum of 30 but not more than 100
noninflammatory lesions (open comedones and closed comedones) on the face (excluding
the nose).

6. Agree to use the provided study products as their only acne treatment, facial wash
and facial moisturizer for the duration of the study.

7. Agree to refrain from temporary and permanent tattoos, paint, or other facial art
(including, but not limited to piercings), cosmetic procedures and devices
(including, but not limited to facial peels, microdermabrasion and Clarisonic®) on
the face for the duration of the study.

8. Subjects aged 12-17 must be willing to read and provide written informed
consent/assent in conjunction with a parent/legal guardian who is able and willing to
read and provide written consent prior to any study related procedure or subjects
aged 18 and older must be willing to read and provide written informed consent prior
to any study related procedures.

9. Subjects apprised of the Health Insurance Portability and Accountability Act of 1996
(HIPAA) and applicable state Bill of Rights and are willing to share personal
information and data, as verified by signing a written authorization at Screening.

10. Subjects must be willing and able to attend study visits and fulfill dosing
requirements.

11. Subjects able to follow study instructions and likely to complete all required
visits. In particular, subjects must agree to adhere to the visit schedule and be
compliant with the treatment regimen.

Exclusion Criteria:

1. Subjects with nodules and cysts.

2. Female subjects who are pregnant, nursing or planning a pregnancy during the study.

3. Subjects with facial hair, abnormal pigmented vascular skin lesions, abnormal skin
pigmentation, or body art (tattoos, permanent or temporary) on the face, which could
interfere with subsequent evaluations of dermal responsiveness.

4. Subjects with any systemic or dermatological disorder, a known history of allergies
or other medical conditions, which in the opinion of the principal investigator/BCD,
could interfere with the conduct of the study, interpretation of results or increase
the risk of adverse reactions.

5. Subjects with any known allergies to any of the ingredients listed on the study
product labels (refer to study product‟s PI and/or current labelling).

6. Subjects who have participated in another interventional, investigational drug or
device research study within 30 days of enrollment.

7. Study site staff or sponsor staff, relatives of site staff or sponsor, or other
individuals who would have access to the clinical study protocol.

8. Subjects with a washout period less than 1 week for over-the-counter topical acne
treatments (with active ingredients such as Benzoyl Peroxide, Salicylic Acid, Sulfur
and Resorcinol), prescription topical acne treatment and topical corticosteroids, and
use of cosmetic devices (such as Clarisonic® or similar) and less than 4 weeks for
topical retinoids.

9. Subjects with a washout period less than 4 weeks for systemic prescription acne
treatment and systemic corticosteroids and less than 24 weeks for oral retinoids.

10. Subjects with current sunburn, eczema, atopic dermatitis, perioral dermatitis,
rosacea, or other topical conditions on the area to be treated.

11. Subjects who are at risk in terms of precautions, warnings, and contra-indications
(refer to the study product‟s PI and current labelling).

12. Subjects who foresee unprotected and intense UV exposure during the study (mountain
sports, UV radiation, sunbathing, etc.).

13. Subjects with any visible skin condition or facial hair that could interfere with the
evaluations.

14. Subjects taking or planning to take topical or systemic medications to treat acne
during the course of the study.

15. Subjects taking other medications, supplements, or non-prescription treatments that,
in the opinion of the principal investigator/BCD, could interfere with the test
results including any regimen of steroidal/non-steroidal anti-inflammatory drugs, or
antihistamines, or anabolic steroids.

16. Subjects currently under the treatment for asthma or diabetes (insulin-dependent
only).

17. Subjects with planned surgical or cosmetic procedures of the face during the course
of the study.

18. Subjects with a history of procedures such as microdermabrasion, chemical peels,
intense pulsed light, fillers, Botox®, lasers, photodynamic therapy, red and blue
light therapy, etc. in the last 90 days.